Literature DB >> 8438813

Preterm twins and triplets. A high-risk group for severe respiratory syncytial virus infection.

E A Simoes1, S J King, M V Lehr, J R Groothuis.   

Abstract

OBJECTIVE: To assess the impact of multiple births and crowded homes on the severity of respiratory syncytial virus illness in preterm infants with bronchopulmonary dysplasia. RESEARCH
DESIGN: Retrospective case-control chart review from a prospective longitudinal respiratory illness study.
SETTING: Neonatal High-Risk Follow-Up Clinic (outpatient setting) and tertiary care hospitals (inpatient setting). PARTICIPANTS: Fourteen sets of twins and two sets of triplets followed up between 1983 and 1989 and matched with 34 singleton infants for date of birth (within 3 months) and gestational age (within 1 month). MEASUREMENTS/MAIN
RESULTS: The risk of developing respiratory syncytial virus illness was significantly higher in multiple-birth infants than in singletons (53% vs 24%; P = .01). Multiple-birth infants were also at greater risk for developing pneumonia (24% vs 6%; P = .05) and requiring hospitalization (32% vs 18%; P = .05) than were singletons. Additional risk factors for developing pneumonia and bronchiolitis were examined in all 68 children. Multiple birth (P = .05), gestational age of less than 30 weeks (P = .02), and crowded homes (defined as more than one person living in 19 m2 of living space [P = .002] or more than one child living in 22 m2 of living space [P = .004]) were additional risk factors for developing pneumonia.
CONCLUSION: Multiple-birth preterm infants are at a higher risk of developing pneumonia than are singletons. Additional risk factors for developing pneumonia in preterm infants with bronchopulmonary dysplasia include gestational age of less than 30 weeks and crowded homes. At-risk infants with any of these risk factors should be targeted for prophylactic and therapeutic interventions against respiratory syncytial virus.

Entities:  

Mesh:

Year:  1993        PMID: 8438813     DOI: 10.1001/archpedi.1993.02160270065020

Source DB:  PubMed          Journal:  Am J Dis Child        ISSN: 0002-922X


  12 in total

1.  Severe respiratory syncytial virus infection among otherwise healthy prematurely born infants: What are we trying to prevent?

Authors:  B Law; N Macdonald; J Langley; I Mitchell; D Stephens; E Wang; J Robinson; F Boucher; J McDonald; S Dobson
Journal:  Paediatr Child Health       Date:  1998-11       Impact factor: 2.253

2.  Net cost of palivizumab for respiratory syncytial virus prophylaxis during the 1998/99 season in northern Alberta.

Authors:  S L Lee; P Etches; J L Robinson
Journal:  Paediatr Child Health       Date:  2001-10       Impact factor: 2.253

3.  Predictors and incidence of hospitalization due to respiratory syncytial virus (RSV)-associated lower respiratory tract infection (LRTI) in non-prophylaxed moderate-to-late preterm infants in Bosnia and Herzegovina.

Authors:  Hajrija Maksić; Suada Heljić; Fahrija Skokić; Darinka Šumanović-Glamuzina; Veroslava Milošević; Almir Zlatanović; Notario Gerard
Journal:  Bosn J Basic Med Sci       Date:  2018-08-01       Impact factor: 3.363

Review 4.  Residential crowding and severe respiratory syncytial virus disease among infants and young children: a systematic literature review.

Authors:  Ann D Colosia; Anthony Masaquel; Caroline Breese Hall; Amy M Barrett; Parthiv J Mahadevia; Ram Yogev
Journal:  BMC Infect Dis       Date:  2012-04-20       Impact factor: 3.090

5.  Risk factors for severe respiratory syncytial virus lower respiratory tract infection.

Authors:  Constanze Sommer; Bernhard Resch; Eric A F Simões
Journal:  Open Microbiol J       Date:  2011-12-30

6.  Respiratory syncytial virus associated hospitalizations in preterm infants of 29 to 32 weeks gestational age using a risk score tool for palivizumab prophylaxis.

Authors:  B Resch; V S Bramreiter; S Kurath-Koller; T Freidl; B Urlesberger
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-01-11       Impact factor: 3.267

Review 7.  Emerging drugs for respiratory syncytial virus infection.

Authors:  Wieslawa Olszewska; Peter Openshaw
Journal:  Expert Opin Emerg Drugs       Date:  2009-06       Impact factor: 4.191

8.  Safety and pharmacokinetics of extended use of palivizumab in Saudi Arabian infants and children.

Authors:  Saleh Al-Alaiyan; Paul Pollack; Gerard F Notario
Journal:  Drugs Context       Date:  2015-02-27

9.  Respiratory syncytial virus disease in preterm infants in the U.S. born at 32-35 weeks gestation not receiving immunoprophylaxis.

Authors:  Christopher S Ambrose; Evan J Anderson; Eric A F Simões; Xionghua Wu; Hanaa Elhefni; C Lucy Park; Frangiscos Sifakis; Jessie R Groothuis
Journal:  Pediatr Infect Dis J       Date:  2014-06       Impact factor: 2.129

10.  Epidemiology of bronchiolitis: a description of emergency department visits and hospitalizations in Puerto Rico, 2010-2014.

Authors:  Andrea Rivera-Sepulveda; Enid J Garcia-Rivera
Journal:  Trop Med Health       Date:  2017-10-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.